Non-Small Cell Lung Cancer
Cancer organoid-based drug sensitivity tests have recently been investigated to predict responses to anticancer drugs.
Role of MicroRNAs on Anti-Apoptotic MCL-1/cIAP-2 Gene Expression in Patients With EGFR-Mutated NSCLC
A study that assessed the impact of miR-29a and miR-143 on gene expression in lung cancer.
Patient-derived organoids have shown promise in modeling cancer therapy response.
A study detailed the landscape of lung adenocarcinoma progression.
MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC.
Positive trial results and FDA approvals have changed the standard of care for NSCLC.
Preoperative ctDNA has prognostic value for determining long-term prognosis for NSCLC.
Clinical trial investigators should use a mindful approach when planning to assess HRQOL in NSCLC.
It is reasonable to upgrade ECE of tumor in lymph nodes from R0 to incomplete resection.
Worse clinical outcomes and higher risk for brain metastasis are more likely to happen in patients with metastatic NSCLC.
Advertisement
Expert Interviews on Lung Cancer
Advertisement
